Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 22,451 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathological Processes Clear all
Completed Not applicable Interventional

Prevention of Bleeding in Patient With Cirrhosis Undergoing Dental Extraction

NCT00816127
View directory record Official record
Conditions
Liver Cirrhosis, Coagulopathy
Interventions
Desmopressin, blood transfusion
Drug · Biological
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2009 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Not applicable Interventional

Pilot Study to Determine the Feasibility of Fluconazole for Induction Treatment and Suppression of Relapse of Histoplasmosis in Patients With the Acquired Immunodeficiency Syndrome

NCT00000627
View directory record Official record
Conditions
HIV Infections, Histoplasmosis
Interventions
Fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 23, 2026, 7:26 PM EDT
Completed No phase listed Observational

The Acute Burn Resuscitation Multicenter Prospective Observational Trial

NCT03144427
View directory record Official record
Conditions
Burns, Shock
Interventions
Not listed
Lead sponsor
American Burn Association
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 23, 2026, 7:26 PM EDT
Recruiting Not applicable Interventional

A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome

NCT05535361
View directory record Official record
Conditions
Short Bowel Syndrome
Interventions
Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome
Device
Lead sponsor
Eclipse Regenesis, Inc.
Other
Eligibility
3 Months to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
5
States / cities
Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

NCT02242942
View directory record Official record
Conditions
Lymphocytic Leukemia, Chronic
Interventions
Chlorambucil, Venetoclax, Obinutuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
8
States / cities
Gilbert, Arizona • Duarte, California • La Jolla, California + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 23, 2026, 7:26 PM EDT
Terminated Phase 2 Interventional Results available

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

NCT04083170
View directory record Official record
Conditions
Acute Erythroid Leukemia, Acute Lymphoblastic Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Refractory Anemia
Interventions
Fludarabine, Cyclophosphamide, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Dilanubicel
Drug · Radiation · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
5
States / cities
San Francisco, California • Washington D.C., District of Columbia • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 23, 2026, 7:26 PM EDT
Recruiting Not applicable Interventional

Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths

NCT06217783
View directory record Official record
Conditions
Oncologic Complications and Emergencies
Interventions
Introcan Safety IV Catheter
Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Funk It Cycle Bites on PMS

NCT05900024
View directory record Official record
Conditions
Premenstrual Syndrome
Interventions
Funk It Cycle Bites
Other
Lead sponsor
Funk It Wellness
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 23, 2026, 7:26 PM EDT
Completed No phase listed Observational

Prospective Identification of Long QT Syndrome in Fetal Life

NCT02876380
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Oct 23, 2026, 7:26 PM EDT
Terminated Not applicable Interventional

Arts & Health Education to Improve Health, Resilience, and Well-Being

NCT04154579
View directory record Official record
Conditions
Hypertension, Diabetes, Obesity, COPD, CHF, High Cholesterol, Asthma, Chronic Pain, Multiple Sclerosis, Depression, Anxiety, Heart Diseases, Stroke
Interventions
HeRe We Arts, HeRe We Ed
Behavioral
Lead sponsor
Lisa Gallagher
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Euclid, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 23, 2026, 7:26 PM EDT
Withdrawn Phase 2 Interventional

Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy

NCT02574962
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
H.P. Acthar® Gel
Drug
Lead sponsor
Mamatha Pasnoor, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Kansas City, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 23, 2026, 7:26 PM EDT
Not yet recruiting Phase 1 Interventional

Study of ChoironeX GalKO Porcine Thymokidney Xenotransplantation in End-Stage Renal Disease

NCT07696962
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
ChoironeX GalKO Porcine Thymokidney
Biological
Lead sponsor
Xeno Holdings (US), LLC dba ChoironeX
Industry
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Recruiting Not applicable Interventional

Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia

NCT05724173
View directory record Official record
Conditions
Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked in Syndrome, Muscular Dystrophies
Interventions
BrainGate Neural Interface System
Device
Lead sponsor
Leigh R. Hochberg, MD, PhD.
Other
Eligibility
18 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Stanford, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 1 Interventional

Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma

NCT02669173
View directory record Official record
Conditions
Glioblastoma
Interventions
Capecitabine, Bevacizumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Recruiting Phase 2 Interventional

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

NCT07572383
View directory record Official record
Conditions
Interstitial Lung Disease, Pulmonary Fibrosis
Interventions
[68Ga]CBP8, Gadoterate Meglumine
Drug
Lead sponsor
Peter Caravan
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

NCT00319254
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
SKI-606 (Bosutinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Duarte, California • Santa Monica, California • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Not applicable Interventional Results available

Bilateral Transversus Abdominis Plane Block With Exparel Verus Continuous Epidural Analgesia With Bupivacaine

NCT02996227
View directory record Official record
Conditions
Pain, Postoperative, Major Abdominal Surgery
Interventions
TAP block, Epidural analgesia, EXPAREL, Bupivacaine
Procedure · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 23, 2026, 7:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Thyroid Disease and Chronic Periodontitis

NCT03369405
View directory record Official record
Conditions
Thyroid Diseases, Chronic Periodontitis
Interventions
NO intervention, patient records review only
Other
Lead sponsor
University at Buffalo
Other
Eligibility
35 Years and older
Enrollment
4,965 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 23, 2026, 7:26 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Optimizing Pain Control in Transurethral Resection of the Prostate

NCT04102566
View directory record Official record
Conditions
Pain, BPH With Urinary Obstruction, BPH With Urinary Obstruction With Other Lower Urinary Tract Symptoms
Interventions
Ibuprofen 600 mg, Education
Drug · Behavioral
Lead sponsor
Benaroya Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 23, 2026, 7:26 PM EDT
Suspended Phase 1Phase 2 Interventional

A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma

NCT05101356
View directory record Official record
Conditions
Advanced Adenocarcinoma, Advanced Malignant Solid Neoplasm, Metastatic Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Adenocarcinoma, Recurrent Malignant Solid Neoplasm
Interventions
Antineoplastic Vaccine, Sargramostim, Pembrolizumab
Biological
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2034
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Not applicable Interventional Results available

Study of Psychological and Motor Effects of Testosterone in Adolescents With XXY/Klinefelter Syndrome

NCT01585831
View directory record Official record
Conditions
Klinefelter Syndrome, XXY Syndrome
Interventions
Testosterone gel 1%, Placebo gel
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 18 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Oct 23, 2026, 7:26 PM EDT
Terminated Phase 1 Interventional

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

NCT05429502
View directory record Official record
Conditions
Neuroblastoma
Interventions
Topotecan, Temozolomide, Ribociclib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Months to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • New Hyde Park, New York • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness

NCT05014672
View directory record Official record
Conditions
Primary Biliary Cholangitis, Liver Stiffness
Interventions
Setanaxib, Placebo
Drug
Lead sponsor
Calliditas Therapeutics Suisse SA
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
29
States / cities
Tucson, Arizona • Los Angeles, California • Pasadena, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)

NCT01175395
View directory record Official record
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
IBI-20089/Lucentis
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
55 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 20, 2014 · Synced Oct 23, 2026, 7:26 PM EDT